

Subject: Medical Science Liaison (MSL) Notes - In-Depth Discussion on NeuroGlyde

Date: April 10, 2023

Provider: Dr. James Harper

Title: Neurologist

Institution: City Neurology Clinic

Summary of Key Discussion Points:

1. Introduction:

- Introduced NeuroGlyde, a novel neuroprotective agent, emphasizing its potential in slowing disease progression.
- Discussed ongoing clinical trials and positive early-phase results.

2. Provider's Current Patient Cases:

- Explored Dr. Harper's experience with NeuroGlyde in treating neurodegenerative disorders.
- Discussed improvements in cognitive function observed in Alzheimer's patients.

3. Efficacy and Clinical Data:

- Presented data demonstrating a 40% reduction in annualized relapse rates in multiple sclerosis patients.
- Highlighted significant improvements in quality of life measures.

4. Safety Profile:

- Discussed the favorable safety profile of NeuroGlyde, with no serious adverse events reported in long-term studies.
- Addressed concerns related to potential neurological side effects.

5. Mechanism of Action:

- Explained NeuroGlyde's unique mechanism targeting neuroinflammation.
- Quantified its efficacy by discussing a 30% reduction in inflammatory biomarkers.

6. Patient Adherence and Education:

- Explored strategies for enhancing patient adherence, including simplified dosing regimens.
- Shared educational materials tailored for both patients and caregivers.

7. Emerging Research and Future Developments:

- Highlighted ongoing research on NeuroGlyde's potential in Parkinson's disease.
- Discussed plans for expanded access programs and patient registries.

8. Competitive Landscape:

- Compared NeuroGlyde to current neuroprotective therapies, emphasizing its disease-modifying potential.
- Discussed NeuroGlyde's cost-effectiveness compared to alternative treatments.

9. Access and Reimbursement:

- Provided updates on access and reimbursement programs.
- Shared insights into patient assistance programs, ensuring affordability.

10. Action Items and Follow-Up:

- Dr. Harper expressed interest in participating in upcoming clinical trials.
- Agreed upon a follow-up in one month to provide trial details and discuss potential collaboration.

11. Closing Remarks:

- Expressed gratitude for Dr. Harper's engagement and interest in advancing neurodegenerative research.
- Reiterated commitment to ongoing collaboration and support.